Optain Health

Market position

Optain positions itself in frontline screening rather than downstream diagnostics, emphasizing clinical value, affordability and ease of use for an overburdened primary care network. Its lead investor characterizes the company as deploying AI at the edge within clinical workflows and as a potential upstream gateway in primary care for AI-driven diagnoses. EyePACS, which Optain acquired, is described as the largest teleophthalmology group in the U.S.

Differentiation is framed around a single non-invasive retinal image that screens for multiple eye and systemic conditions, portable robotic capture without pupil dilation or trained operators, and a combination of on-device AI with teleophthalmology grading, positioned as affordable and simple enough for population-level screening in primary care.

Technology

The platform pairs a portable robotic fundus camera that captures retinal images without pupil dilation with AI models that assess image quality and detect abnormalities such as lesions, vascular patterns and optic nerve changes. Detected conditions include diabetic retinopathy, glaucoma and age-related macular degeneration, alongside cardiovascular disease risk assessment. The company states it houses millions of retinal images and employs AI specialists; capture is described as taking under one minute, operable by untrained staff in lit rooms, with patient guidance in seven languages. A teleophthalmology grading service supplements automated analysis in the U.S.

Go-to-market

Optain sells into enterprise health system deployments and frontline care settings, using strategic investment from health systems as a distribution channel: seven U.S. health systems that invested in the Series A, collectively serving 28 million patients across 25 states, each began deploying the platform across their networks. The acquisition of EyePACS added a nationwide teleophthalmology network. Additional investors are supporting expansion in Australia, Europe, the Middle East and Southeast Asia.

Primary care practices, optometry, health systems and other frontline care settings conducting screening, including community health fairs; ultimate beneficiaries include diabetic patients requiring annual retinal screening and underserved populations with limited access to specialist eye care.

Geography

Headquartered in New York City with Australian roots and R&D; the company stated plans for significant new Australian R&D investment and local team growth to lead expansion outside the U.S., with a global footprint targeted across Australia, Europe, the Middle East and Southeast Asia. Health system deployments span 25 U.S. states.

History

Optain states that its roots trace to Eyetelligence, an Australian-founded company launched in 2019. Optain Health was co-created in 2023 by Aegis Ventures, which also formed the Aegis Digital Consortium, a collaboration of leading U.S. regional health systems that co-develops AI-driven healthtech companies (described as 11 health systems in a September 2025 release and 14 in a March 2026 profile). Jeff Dunkel was approached in 2023 to lead the company as CEO, following prior roles including CSO at Mindset Medical, EVP of Strategy at Titan Spine and CEO of NuHope. In September 2025 the company closed a $26 million Series A led by Insight Partners and, in the same timeframe, acquired EyePACS, a teleophthalmology group with which it had partnered for the prior two years.